MALDI‐TOF MS profiling as the first‐tier screen for sickle cell disease in neonates: Matching throughput to objectives
PROTEOMICS - CLINICAL APPLICATIONS2011Vol. 5(7-8), pp. 405–414
Citations Over TimeTop 24% of 2011 papers
Johan Hachani, Sophie Duban‐Deweer, Gwënaël Pottiez, Gilles Renom, Christophe Flahaut, Jean‐Marc Périni
Abstract
Given that the overall acquisition, data reprocessing and software-assisted classification (ClinProTools™) time for processing four mass determinations (corresponding to one sample) was around 1 min, 1000 samples can be analysed per day. Rather than seeking to detect as many different haemoglobinopathies as possible, it would become possible to use MALDI-TOF-MS to screen (at a constant cost) as many samples as possible for sickle cell disease.
Related Papers
- → The use of dried blood spot samples in the diagnosis of lysosomal storage disorders — Current status and perspectives(2011)83 cited
- → Newborn Screening for Mucopolysaccharidoses: Results of a Pilot Study with 100 000 Dried Blood Spots(2019)42 cited
- → Newborn screening residual dried blood spot use for newborn screening quality improvement(2010)12 cited
- → Applications of Dried Blood Spots in Newborn and Metabolic Screening(2014)9 cited
- → Analytical Perspectives on the Use of Dried Blood Spots and Mass Spectrometry in Newborn Screening(2015)3 cited